熱門資訊> 正文
MediWound获得烧伤治疗的儿科适应症NexoBrid
2024-08-19 00:49
- The U.S. FDA has approved use of MediWound's (NASDAQ:MDWD) burn treatment NexoBrid in pediatric patients as young as newborns.
- NexoBrid (anacaulase) is intended for removal of eschar -- dead tissue that forms over healthy skin -- for patients with deep partial- and/or full-thickness thermal burns.
- Approval was based on phase 3 data from hospitalized pediatric patients, and pediatric data from other phase III and phase II trials conducted during NexoBrid's development.
More on MediWound
- MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript
- MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript
- MediWound Q2 2024 Earnings Preview
- MediWound rises on €16.25 million funding from European Innovation Council
- Seeking Alpha’s Quant Rating on MediWound
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
